Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.

Cancer treatment reviews - 1 Dec 2019

Lian Tong, Li Changying, Wang Haitao

Abstract excerpt

The aberrant activation of RAS-derived mitogen-activated protein kinase (MAPK) signaling pathway plays a prominent role in tumorigenesis of an array of malignancies. The reasons are usually the upstream activated mutations including mitogen-activated protein kinase kinase 1/2 (MEK1/2). As oncogenic mutations, MEK1 mutations have been observed in a variety of malignancies including melanoma, histiocytic neoplasms,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Histiocytosis, Langerhans-Cell
Share to Liver Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to NIH 3T3 Cells

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 31715422
DOI: 10.1016/j.ctrv.2019.101907

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.PMID 31715422Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.Semantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.Semantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

MEK and the inhibitors: from bench to bedsideSemantic proximity Read ↗

Integrative Pan-cancer Analysis of MEK1 Aberrations and the Potential Clinical ImplicationsSemantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Trametinib (GSK1120212) in the treatment of melanomaSemantic proximity Read ↗

Improved survival with MEK inhibition in BRAF-mutated melanoma.Semantic proximity Read ↗

Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic OverviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.